Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Beijing Firm Launches Clinical Trial On Stem Cell Treatment For Diabetes

This article was originally published in PharmAsia News

Executive Summary

BEIJING - The chief executive officer of the Beijing-headquartered firm Cellonis says that preliminary results from an ongoing clinical trial in the Chinese capital are a promising sign of the potential for widening use of a stem cell-based treatment for diabetes in the future

You may also be interested in...

GSK Carving Out Strategic Strengths In Emerging Markets: Euro-Biotech Partnering Summit

GSK VP Paul Bolno on market-specific opportunities in Asia.

Geron Restructuring Sours Investors As Company Bets On Cancer

The pioneering U.S. biotech will look to partner its five human embryonic stem cell research programs while focusing entirely on two mid-stage cancer assets.

China At Ground Zero In Explosion of New Diabetes Cases; International Federation Now Projects 500 Million Diabetics Worldwide By 2030

BEIJING - A vast new study conducted by scientists in North America and Asia places China at ground zero in terms of an explosion in the incidence of diabetes, and "shows that the global burden of diabetes is far larger than previously estimated," according to a scholar at the Brussels, Belgium-based International Diabetes Federation

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts